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In Alzheimer disease (AD) patient brains, the accumulation of amyloid-β (Aβ) peptides is associated with activated microglia.
Aβ is derived from the amyloid precursor protein; two major forms of Aβ, that is, Aβ1-40 (Aβ40) and Aβ1-42 (Aβ42), exist.
We previously reported that rat microglia phagocytose Aβ42, and high mobility group box protein 1 (HMGB1), a chromosomal
protein, inhibits phagocytosis. In the present study, we investigated the eﬀects of exogenous HMGB1 on rat microglial Aβ40
phagocytosis. In the presence of exogenous HMGB1, Aβ40 markedly increased in microglial cytoplasm, and the reduction
of extracellular Aβ40 was inhibited. During this period, HMGB1 was colocalized with Aβ40 in the cytoplasm. Furthermore,
exogenousHMGB1inhibitedthedegradationofAβ40inducedbytheratmicroglialcytosolicfraction.Thus,extracellularHMGB1
may internalize with Aβ40 in the microglial cytoplasm and inhibit Aβ40 degradation by microglia. This may subsequently
delay Aβ40 clearance. We further conﬁrmed that in AD brains, the parts of senile plaques surrounded by activated microglia
are composed of Aβ40, and extracellular HMGB1 is deposited on these plaques. Taken together, microglial Aβ phagocytosis
dysfunction may be caused by HMGB1 that accumulates extracellularly on Aβ plaques, and it may be critically involved in the
pathological progression of AD.
1.Introduction
Alzheimer’s disease (AD) is characterized by the deposition
of amyloid-β (Aβ) plaques, accumulation of neuroﬁbrillary
t a n g l e s( N F T s ) ,a n dl o s so fs y n a p s e sa n dn e u r o n si np a r t i c -
ular brain areas [1]. Experimental studies using transgenic
AD mouse models have demonstrated that Aβ accelerates
NFT formation [2, 3] and is closely associated with synaptic
damage [4]. In contrast, Aβ r e d u c t i o ni nt h eb r a i nb yA β
immunization restores cognitive functions in transgenic AD
mouse models [5–9] and also appears to slow cognitive
decline in human AD patients [10]. Thus, the accumulation
of Aβ may play a key role in the pathogenesis of AD
[11].
Aβ is derived from the sequential proteolysis of amyloid
precursor protein (APP) by β-a n dγ-secretases and is
composed of 37–43 amino acid residues because γ-secretase,
which is a protein complex including presenilin (PS),
generates the C-terminal of Aβ with diﬀerent lengths [12].
Among the variations in Aβ,A β1-40 (Aβ40) and Aβ1-42
(Aβ42) are the major species found in AD brains. The most
predominant species deposited in Aβ plaques is Aβ42 [13],
which is prone to aggregation [14] and indicates increased
neurotoxicity [15]. On the other hand, Aβ40 is the major2 International Journal of Alzheimer’s Disease
soluble species; its secretion is 10-fold more than that of
Aβ42 in normal brains. A previous study demonstrated that
thedepositionofAβ40inADbrainsisparticularlycorrelated
with synaptic and neuronal loss [16]. Thus, lowering the
concentration of Aβ40 and Aβ42 in the brain may serve as
a disease-modifying therapy for AD patients.
Activated microglia accumulate on Aβ plaques in AD
brains. Although microglial accumulation was initially
believed to be involved in the formation of Aβ plaques
[17], experimental studies later demonstrated the ability of
microglia to phagocytose Aβ peptides [18, 19]. In addition,
we demonstrated microglial contribution in Aβ42 clearance
using primary cultured rat microglia [20–25]. However,
it has been reported that microglial dystrophy occurs in
aging human brains [26], and the age-related disability of
microglial Aβ phagocytosis has been demonstrated experi-
mentally[27].Thus,thedysfunctionofmicroglialAβ phago-
cytosis appears to be closely involved in the progression of
AD pathology.
High-mobility group box protein 1 (HMGB1) is an
abundant nonhistone chromosomal protein that is released
from cells undergoing necrosis [28, 29]. The released
HMGB1 behaves like an inﬂammatory mediator by acting
on receptor for advanced glycation end products (RAGE)
and Toll-like receptors (TLRs) 2 and 4 [30, 31]. We
have previously reported that HMGB1 is extracellularly
associated with Aβ plaques in AD brain and is involved
in the pathogenesis of AD as an inhibitory factor against
microglial Aβ42 phagocytosis by interfering with uptake
[32, 33]. However, the eﬀect of extracellular HMGB1 on the
microglial phagocytosis of Aβ40, but not Aβ42, has not been
elucidated. Therefore, in the present study, we analyzed rat
microglial Aβ40 phagocytosis in the presence and absence of
exogenous HMGB1.
2.MaterialsandMethods
2.1. Primary Culture of Rat Microglia and Drug Treat-
ment. The primary culture experimental procedure was
reviewed and approved by the Committee for Animal
Research at Kyoto Pharmaceutical University. Primary cul-
tured microglia (over 97% pure) were prepared, as described
previously [32]. Brieﬂy, brain tissues were isolated from
newborn Wistar rats, minced, and gently dissociated by
trituration in Dulbecco’s modiﬁed Eagle medium (DMEM).
The tissue suspension was ﬁltered through a 50μm diameter
nylon mesh into 50mL tubes, and cells were collected by
centrifugation at 200×g for 10min. Cells were resuspended
inDMEMwith10%fetalcalfserum,100units/mLpenicillin,
and 100μg/mL streptomycin; they were then plated onto
100mmdiameterdishesat37◦Cinhumidiﬁed5%CO2/95%
air. We then harvested the ﬂoating microglia from mixed
glial cultures. Microglia were transferred to 24-well plates
(3.0 × 105 cells/well) and were allowed to adhere at 37◦C
overnight; they were then treated with sterilized phosphate-
buﬀered saline (PBS) as the vehicle or synthetic human Aβs
(Aβ40 or Aβ42; Anaspec, San Jose, CA) in the presence or
absenceofcalfthymus-puriﬁed HMGB1(WAKOChemicals,
Osaka, Japan). We previously demonstrated that 1μMA β42
for 12h markedly phagocytosed by rat microglia [20], and
0.3μM HMGB1 inhibits the phagocytosis [32, 33]. When
Aβ40 at 1–3μM were added into the culture, we could
detect Aβ40 phagocytosed by rat microglia by Western blot
analysis [25]. Therefore, in the present study, we adopted the
concentrations at 1μMa n d0 . 3μM for the treatments with
Aβs and HMGB1, respectively. To make the experimental
conditions more accurate, we dissolved the lyophilized
human Aβ peptides in distilled and sterilized water at a high
concentration, and small aliquots were kept at −80◦C until
use. Subsequently, Aβ stock solutions were diluted using
sterilized PBS, and once Aβ was thawed, no Aβ was refrozen
to eliminate variance due to repeated freezing and thawing.
2.2. Immunocytochemistry. Twelve hours after Aβ treatment,
microglia were gently rinsed three times with PBS and
then ﬁxed with 4% paraformaldehyde in 100mM phosphate
buﬀer (PB) for 30min. Cells were then incubated with
a mouse monoclonal antibody against Aβ (clone 6E10,
1:1000; Chemicon, Temecula, CA) and a rabbit polyclonal
antibody against HMGB1 (1:1000; BD Pharmingen, San
Diego, CA). The primary antibodies were followed by appli-
cation of a rhodamine-labeled anti-mouse immunoglobu-
lin (Ig)G antibody and ﬂuorescein isothiocyanate-labeled
anti-rabbit IgG antibody (each diluted 1:500; Molecular
Probes, Eugene, OR). Furthermore, cells were incubated
with Hoechst 33258 (1:5000; Molecular Probes) to visualize
microglial nuclei. Labeled ﬂuorescence was detected using
a laser scanning confocal microscope LSM 510 (Carl Zeiss,
Jena, Germany).
2.3. Aβ Phagocytosis and Clearance Assay by Western Blot
Analysis. Twelve hours after Aβ treatment, microglia and
culture media were collected and lysed with Laemmli’s
sample buﬀer and then analyzed by Western blot analysis.
Brieﬂy, samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE; 20% poly-
acrylamide gels in Tricine buﬀer). Proteins were transferred
to a polyvinylidene diﬂuoride membrane (Millipore, Biller-
ica, MA) by electroelution and then incubated with a mouse
monoclonal antibody against Aβ (clone 6E10, 1:2000;
Chemicon), followed by a horseradish peroxidase-linked
secondaryantibodyagainstmouseIgG(1:1,000;Amersham,
Buckinghamshire, UK). Subsequently, protein bands were
detectedon radiographic ﬁlms (Kodak, Rochester,NY) using
a chemiluminescence kit (ECL kit; Amersham). For semi-
quantitative analysis, radiographic ﬁlms were scanned with a
CCD color scanner (DuoScan, AGFA, Mortsel, Belgium) and
then analyzed densitometrically using the public domain US
National Institutes of Health image 1.56 program.
2.4. Aβ Degradation Assay. Microglia were harvested and
resuspended in 100mM Tris-HCl buﬀer (pH 7.5) containing
10mM KCl, 1.5mM MgCl2, and 1mM DTT and then
homogenized. After centrifugation (50,000×g) for 20min
at 4◦C, the protein concentration of the supernatant was
measured and used as the microglial cytosolic fraction.International Journal of Alzheimer’s Disease 3
The Aβ peptide (3μMA β40 or Aβ42) was incubated with
the microglial cytosolic fraction (ﬁnal concentration of
1mg/mL) in the presence or absence of 0.3μMH M G B 1 .A t
the time points of 0, 6, and 12h after incubation, Laemmli’s
sample buﬀer was added, and samples were boiled at 100◦C
for 5min to stop Aβ degradation. Subsequently, samples
were analyzed using the antibody against Aβ (clone 6E10,
1:2000; Chemicon) by Western blot analysis, as described
previously.
2.5. Immunoprecipitation. HMGB1 (1.5μg, 2.6μM) was
mixed with 3μg of synthetic Aβ40 (37.5μM) in PBS.
Twenty-four hours after incubation, the antibody (10μg
of IgG) against HMGB1 (BD Pharmingen) or Aβ (clone
6E10; Chemicon) was added to the mixture and further
incubated for 2h at 4◦C. Protein A-Sepharose (50μLo fa
50% slurry) was then added, and the mixture was incubated
overnight at 4◦C. After centrifugation, immunoprecipitates
were resuspended in Laemmli’s sample buﬀer. Subsequently,
samples were analyzed using the antibody against HMGB1
(1:1000; BD Pharmingen) or Aβ (clone 6E10, 1:2000;
Chemicon) by Western blot analysis, as described previously.
2.6. Immunohistochemical Study Using Human AD Brain
Sections. All experiments using human samples were per-
formed in accordance with the guidelines of the ethical
committees of Kyoto Pharmaceutical University. Informed
consent was obtained from all subjects. For histological
examination, frontal cortex tissue from a patient who was
clinically and histopathologically diagnosed as human AD
(age, 67 years) was used. Neuropathological assessment of
AD was conducted in accordance with the criteria of the
Consortium to Establish a Registry for Alzheimer’s Disease
(CERAD).Dissectedtissueblockswereﬁxedin10%formalin
and transferred to a 15% sucrose solution in 100mM PB
containing 0.1% sodium azide at 4◦C. The cryoprotected
brain blocks were cut into 20μm sections on a cryostat, and
the collected sections were stored in PBS containing 0.3%
Triton X-100 (PBS-T) and 0.1% sodium azide at 4◦C until
use.
Immunohistochemical study was essentially performed
as described previously [34]. Free-ﬂoating human brain
sections were treated with 0.1% hydrogen peroxide for
30min to quench endogenous peroxidase activity; they were
then incubated with 1% goat serum to block nonspeciﬁc
binding in PBS. Sections were then incubated with a mouse
monoclonal antibody against Aβ40 (1:1000; nanoTools,
Teningen, Germany) and rabbit polyclonal antibody against
Aβ42 (1:1000; IBL, Gunma, Japan), a rabbit polyclonal anti-
body against Aβ40 (1:1000; IBL) and mouse monoclonal
antibody against human leukemia antigen (HLA)-DR (1:50;
Dako, Glostrup, Denmark), or a rabbit polyclonal antibody
against Aβ42 (1:1000; IBL) and mouse monoclonal anti-
body against HLA-DR (1:50; Dako) in PBS-T with 0.1%
sodium azide for 4 days at 4◦C. After washing with PBS-T,
the sections were incubated with biotinylated anti-rabbit IgG
antibody (1:2000; Vector Laboratories, Burlingame, CA) for
2h at room temperature. The sections were then incubated
with avidin peroxidase (1:4000; ABC Elite Kit; Vector Labo-
ratories) for 1h at room temperature. Subsequently, labeling
was visualized by incubation with 50mM Tris-HCl buﬀer
(pH 7.6) containing 0.02% 3,3 -diaminobenzidine (DAB)
and 0.0045% hydrogen peroxide with nickel enhancement
using 0.6% nickel ammonium sulfate, which yielded a dark
blue color. In the second cycle, sections were incubated
withabiotinylatedanti-mouseIgGantibody(1:2000;Vector
Laboratories) for 2h at room temperature. The sections
were then incubated with avidin peroxidase (1:4000; ABC
Elite Kit; Vector Laboratories) for 1h at room temperature.
Subsequently, the DAB reaction was performed without
nickel ammonium sulfate, which yielded a brown color.
In laser confocal microscopic analysis, human AD brain
sections were treated with 1% goat serum to block nonspe-
ciﬁc binding in PBS. Sections were then coincubated with a
rabbit polyclonal antibody against Aβ40 (1:1000; IBL) and a
mouse monoclonal antibody against HLA-DR (1:50; Dako)
or a mouse monoclonal antibody against Aβ40 (1:1000;
nanoTools)andarabbitpolyclonalantibodyagainstHMGB1
(1:1000;BDPharmingen)inPBS-Twith0.1%sodiumazide
for 4 days at 4◦C. The primary antibodies were probed
with Alexa Fluor 546-labeled anti-rabbit IgG antibody and
Alexia Fluor 488-labeled anti-mouse IgG antibody or Alexa
Fluor 546-labeled anti-mouse IgG antibody and Alexia Fluor
488-labeled anti-rabbit IgG antibody (each diluted 1:500;
Molecular Probes). Subsequently, ﬂuorescence was observed
using a laser scanning confocal microscope LSM 510 (Carl
Zeiss).
2.7. Statistical Evaluation. Results of the densitometric anal-
ysis are given as the mean ± standard error of mean.
The statistical signiﬁcance of diﬀerences was determined by
analysis of variance. Further statistical analysis for post hoc
comparisons was conducted using the Bonferroni/Dunn test
(StatView, Abacus Concepts, Berkeley, CA).
3. Results
3.1. Binding of HMGB1 with Aβ40. In our previous study,
we found that HMGB1 is extracellularly accumulated on
Aβ plaques in AD brains and further demonstrated that
HMGB1 binds to Aβ42 in in vitro cell-free study [33]. In
the present cell-free study, we ﬁrst examined the binding
aﬃnity of HMGB1 for Aβ40. Following incubation of the
HMGB1 peptide alone, a 29kDa band of HMGB1 and its
high-molecular-weight aggregates was detected, while an
approximately 33kDa band (arrow in Figure 1(a)), which is
believed to be a complex of HMGB1 and Aβ40, appeared as
an upper band 6h after incubation of HMGB1 and Aβ40
peptides (Figure 1(a)). Following incubation with Aβ40
(Figure 1(b)), monomers and oligomers of Aβ40 were the
major components present in the absence of HMGB1 at each
time point. Predictably, the 33kDa band, which seemed to
be a complex of HMGB1 and Aβ40, was detected by the
addition of the HMGB1 peptide (arrow in Figure 1(b)).
To conﬁrm the binding aﬃnity between HMGB1 and
Aβ40, we further examined immunoprecipitation using the4 International Journal of Alzheimer’s Disease
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Figure 1:BindingaﬃnityofHMGB1forAβ40.(a,b)AfterincubationofHMGB1,Aβ40,andthemixtureofHMGB1withAβ40for0,6,and
24h, samples were analyzed by Western blot analysis using the anti-HMGB1 antibody (a) or anti-Aβ antibody (b). (c, d) After incubation of
HMGB1, Aβ40, and the mixture of HMGB with Aβ40 for 24h, samples were immunoprecipitated using the anti-HMGB1 antibody (c) or
anti-Aβ antibody (d). The precipitates were then analyzed by Western blot analysis using the anti-HMGB1 antibody and anti-Aβ antibody.
anti-HMGB1 antibody (Figure 1(c)) or anti-Aβ antibody
(Figure 1(d)). As a result, in the mixture of HMGB1 and
Aβ, the complex of HMGB1 and Aβ40 (approximately
33kDa) was immunoprecipitated with A-Sepharose-linked
antibodiesagainstHMGB1(Figure1(c))orAβ(Figure1(d)).
These results demonstrated that HMGB1 had a binding
aﬃnity for Aβ40.
3.2. Microglial Aβ Phagocytosis and Eﬀect of Exoge-
nous HMGB1. We previously demonstrated that microglia
markedly phagocytose Aβ42 [25], and extracellular HMGB1
inhibits phagocytosis on the cell surface [32, 33]. In the
present study, we analyzed the microglial Aβ40 phagocytosis
and the eﬀects of extracellular HMGB1 on phagocytosis
using laser confocal microscopy (Figure 2). Endogenous
HMGB1 was detected in the nuclei of primary cultured rat
microglia (Figures 2(a)–2(f), cyan). When treated with the
vehicle (Figure 2(a)) or HMGB1 alone (Figure 2(b)), no
Aβ immunoreactivitywasdetected.Consistentwithprevious
studies, in the presence of Aβ42, microglia phagocytosed
Aβ42 (Figure 2(c), red), exogenous HMGB1 was colocal-
ized with Aβ42 on the microglial cell surface, and Aβ
internalization was inhibited (Figure 2(d), yellow). When
treated with Aβ40, the immunoreactivity of Aβ40 was barely
detected in the microglial cytoplasm (Figure 2(e), red).
Interestingly, in the presence of exogenous HMGB1, small
vesicle-like immunoreactivities of Aβ40 (Figure 2(f), red)
and HMGB1 (Figure 2(f), green) were markedly increased in
the microglial cytoplasm, and parts of them were colocalized
with each other (Figure 2(f), yellow).
3.3. Amounts of Aβ40 inside and outside Microglia and Eﬀect
of Exogenous HMGB1. Twelve hours after Aβ40 treatment,
microglialcelllysateandconditionedmediumwerecollected
and subjected to Western blot analysis; semiquantitative
analysis was then examined to measure the concentrationInternational Journal of Alzheimer’s Disease 5
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Figure 2: Eﬀect of exogenous HMGB1 on microglial Aβ phagocytosis analyzed by laser confocal microscopy. Rat microglia were incubated
with the vehicle (a), HMGB1 (b), Aβ42 (c), Aβ42 and HMGB1 (d), Aβ40 (e), or Aβ40 and HMGB1 (f) for 12h. Fixed cells were further
incubated with the anti-Aβ antibody (red), anti-HMGB1 antibody (green), and Hoechst 33258 (dye for nuclei; blue); they were analyzed
using a laser scanning confocal microscope. DIC: diﬀerential interference contrast. Scale bar = 20μm for all panels.
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Figure 3: Eﬀect of exogenous HMGB1 on microglial Aβ phagocytosis analyzed by Western blot. Rat microglia were incubated with the
v e h i c l e ,H M G B 1 ,A β40, or Aβ40 and HMGB1 for 12h. Microglial cell lysate (a) and conditioned medium (b) were then subjected to
Western blot analysis using the anti-Aβ antibody, and then the amounts of Aβ40 inside (a) and outside microglia (b) were semiquantitatively
measured. ∗P<0.05, ∗∗∗P<0.001 versus treatment with Aβ40 alone.6 International Journal of Alzheimer’s Disease
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Figure 4: Aβ degradation with the microglial cytosolic fraction. (a) Aβ40 and Aβ42 were incubated with the rat microglial cytosolic fraction
for 0, 6, and 24h. After incubation, samples were subjected to Western blot analysis using the anti-Aβ antibody, and the amount of Aβ was
semiquantitatively measured. ∗∗P<0.01, ∗∗∗P<0.001 versus time point 0h. †††P<0.001 versus Aβ40 at time point 24h. (b) Aβ40 and
Aβ40 with HMGB1 were incubated with rat microglial cytosolic fractions for 0, 6, and 24h. After incubation, the samples were subjected to
Western blot analysis using the anti-Aβ antibody, and the amount of Aβ was semiquantitatively measured. ∗∗P<0.01, ∗∗∗P<0.001 versus
Aβ40 alone at each time point.
of Aβ40 inside (Figure 3(a)) and outside microglia (Fig-
ure 3(b)). When microglia were treated with the vehicle
or exogenous HMGB1 alone, no Aβ40 immunoreactivity
was detected inside them (Figure 3(a)). After treatment
with Aβ40, a small amount of Aβ40 was detected inside
microglia (Aβ40 phagocytosed by microglia), and this
amount increased dramatically by simultaneous treatment
with exogenous HMGB1 (Figure 3(a)). This result raises two
possibilities: (i) extracellular HMGB1 increases microglial
Aβ40 uptake, and (ii) HMGB1 inhibits the degradation of
Aβ40 in the microglial cytoplasm after uptake. To address
these possibilities, we measured the amount of Aβ40 in
the culture medium (Aβ40 remaining outside microglia)
(Figure 3(b)). After treatment with the vehicle or exogenous
HMGB1 alone, no Aβ was detected in the culture medium.
Twelve hours after Aβ40 treatment, the amount of Aβ40 in
the culture medium signiﬁcantly increased by simultaneous
treatment with exogenous HMGB1. Thus, in the presence of
exogenous HMGB1, the amount of Aβ40 both inside and
outside microglia was much higher than that when treated
with Aβ40 alone. These results suggest that exogenous
HMGB1 phagocytosed by microglia inhibits the degradation
of Aβ40 in the microglial cytoplasm and subsequently delays
Aβ clearance by microglia.
3.4. Aβ Degradation with the Microglial Cytosol Fraction and
Eﬀect of Exogenous HMGB1. To conﬁrm whether exogenous
HMGB1 inhibits Aβ40 degradation in microglial cyto-
plasm, we prepared cytosolic fractions from rat microglia
and mixed them with Aβ. Degradation of Aβ40 and
Aβ42 by microglial cytosol fractions was compared (Fig-
ure 4(a)). Aβ40 and Aβ42 were gradually degraded by the
addition of the microglial cytosolic fraction in a time-
dependent manner. Aβ40 was degraded earlier than Aβ42
(Figure 4(a)). We next examined the eﬀect of exoge-
nous HMGB1 on the Aβ40 degradation induced by the
microglial cytosolic fraction (Figure 4(b)). At 6 and 24h
after incubation, the degradation of Aβ40 was signiﬁcantly
delayed by the addition of exogenous HMGB1. Thus, this
result suggests that exogenous HMGB1 phagocytosed by
microglia inhibits the degradation of Aβ40 in the microglial
cytoplasm.
3.5.AccumulationofAβ40,Aβ42,andMicrogliainADBrains.
We further investigated the localization of Aβ40 and Aβ42 in
AD brains using speciﬁc antibodies (Figures 5(a) and 5(b))
and microglial accumulation on the plaques composed of
Aβ40 (Figures 5(c) and 5(d))a n dA β42 (Figures 5(e) andInternational Journal of Alzheimer’s Disease 7
Low-magnification
A
β
4
0
 
(
d
a
r
k
 
b
l
u
e
)
A
β
4
2
 
(
b
r
o
w
n
)
(a)
High-magnification
(b)
A
β
4
0
 
(
d
a
r
k
 
b
l
u
e
)
H
L
A
-
D
R
 
(
b
r
o
w
n
)
(c) (d)
A
β
4
2
 
(
d
a
r
k
 
b
l
u
e
)
H
L
A
-
D
R
 
(
b
r
o
w
n
)
(e) (f)
Figure 5: Immunohistochemical study of microglial accumulation on Aβ plaques in human AD brains. Free-ﬂoating human AD brain
sections were incubated with the anti-Aβ40 speciﬁc antibody (dark blue) and anti-Aβ42 speciﬁc antibody (brown) (a, b), anti-Aβ40 speciﬁc
antibody (dark blue) and anti-HLA-DR antibody (for microglial staining; brown) (c, d), and anti-Aβ42 speciﬁc antibody (dark blue)
and anti-HLA-DR antibody (for microglial staining; brown). Arrows and arrow heads show marked and poor microglial accumulations,
respectively. (b), (d), and (f) show high-magniﬁcation views of squared area in (a), (c), and (e), respectively. Scale bar in (a) equals 400μm
for (a), (c), and (e). Scale bar in (b) equals 100μm for (b), (d), and (f).
5(f)). The number of Aβ40 plaques (dark blue deposits in
Figure 5(a)) was lesser than that of Aβ42 plaques (brown
deposits in Figure 5(a)). High-magniﬁcation photographs
revealed that Aβ40 accumulated on Aβ42 plaques (Fig-
ure5(b)).Regardingmicroglialaccumulations(Figures5(c)–
5(f)), almost all Aβ40 plaques were markedly surrounded by
activated microglia (Figure 5(c) and arrows in Figure 5(d)).
AlthoughsomeAβ42plaquesweremarkedlyaccumulatedby
microglia (Figure 5(e) and arrow in Figure 5(f)), others were
moderately or poorly surrounded by microglia (arrowheads
in Figure 5(f)).
3.6. Accumulation of HMGB1 and Microglia on Aβ40 Plaques
in AD Brains. We previously demonstrated that extracellular
HMGB1 accumulates on Aβ plaques, as detected using an
anti-Aβ a n t i b o d yt h a tr e a c t sw i t hab r o a ds p e c t r u mo fA β
species [33]. Therefore, in the present study, we investigated
the colocalization of extracellular HMGB1 on Aβ40 plaques
in AD brains using a speciﬁc anti-Aβ40 antibody. Consistent
with the immunohistochemical study (Figures 5(c) and
5(d)), microglia (Figure 6(b)) markedly accumulated on
Aβ40 plaques (Figure 6(a)) in AD brains (Figure 6(c)).
We further demonstrated that extracellular HMGB18 International Journal of Alzheimer’s Disease
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Figure 6: Laser confocal microscopic study on the accumulation of HMGB1 and microglia on Aβ40 plaques in human AD brains. (a–c)
Free-ﬂoating human AD brain sections were incubated with the anti-Aβ40 speciﬁc antibody ((a) red) and anti-HLA-DR antibody ((b) for
microglial staining, green). The merged image is indicated in (c). (d–f) Free-ﬂoating human AD brain sections were incubated with the
anti-Aβ40 speciﬁc antibody ((a); red) and anti-HMGB1 antibody ((b); green). The merged image is indicated in (f). Scale bar in (a) equals
50μm for all panels.
(Figure 6(e)) colocalized with Aβ40 plaques (Figure 6(d))i n
AD brains (Figure 6(f)).
4. Discussion
In studies on familial AD, mutations in the APP, PS1,a n d
PS2 genes have been detected, and transgenic mice models
carrying these familial AD-linked mutations show enhanced
Aβ production in their brains. In particular, transgenic mice
carryingtheAPP mutationdisplaycharacteristicsthatclosely
resemble AD, such as Aβ deposition and memory dysfunc-
tion [35, 36], and introduction of the double mutations of
PS/APP exhibits the early onset of these pathologies [37].
Thus, all mutations are involved in Aβ generation, and the
accumulation of Aβ in the brain has been strongly suggested
to be the primary event driving the pathogenesis of AD.
However, familial AD accounts for less than 1% of all AD
cases [38]; most cases develop sporadically. Although the
etiology of sporadic AD remains much more elusive than
that of familial cases, neurological and pathological events in
sporadic AD are essentially indistinguishable from those in
familial cases. In sporadic AD, a decreased Aβ clearance rate
has been reported [39].
One proposed mechanism of Aβ clearance is microglial
Aβ phagocytosis [40, 41] .R e p o r t so nA Dp a t i e n t st r e a t e d
with Aβ immunization also indicate microglial contribution
to Aβ clearance in human AD brains [42, 43]. However, it
has been suggested that the ability of microglia to clear Aβ
decreaseswithageandprogressionofADpathology[26,27],
and it may, at least in part, account for the dysregulation of
Aβ clearance in sporadic AD.
HMGB1 inhibits microglial Aβ42 phagocytosis by inter-
fering with Aβ42 internalization [32, 33]. In the present
study, we further showed that exogenous HMGB1 inhibits
the degradation of Aβ40 in rat microglial cytoplasm and
subsequently delays Aβ40 clearance. We demonstrated the
binding aﬃnities of HMGB1 for Aβ40 and Aβ42 [33]. Aβ
contains an amino acid sequence (18VFFA21) that has been
identiﬁed to be essential for aggregation and ﬁbril formation
[44]. Interestingly, HMGB1 contains a homologous motif
(16AFFV19), and this sequence is thought to be critically
involved in the interactions of Aβ with HMGB1 [33, 45].
Among the many peptidases that have been proposed as Aβ-
degrading enzymes [46], insulin-degrading enzyme, cathep-
sin D, and neprilysin are the principle enzymes involved
in microglia-mediated Aβ degradation [25, 47, 48]. Many
cleavage sites that are the targets of microglial Aβ-degrading
enzymes are located on and in the vicinity of the amino
acidsequence(18VFFA21)ofAβ [46].Therefore,wespeculate
that the cleavage sites of Aβ are masked by the binding
of HMGB1; subsequently, the degradation of Aβ40 may be
inhibited in the microglial cytoplasm. In case of Aβ42, Aβ42
itself forms high-molecular-weight ﬁbrils during incubation
[33]. Therefore, the binding of HMGB1 may stabilize Aβ42
ﬁbril formation, and high-molecular-weight complex of
HMGB1 and Aβ42 ﬁbril may interrupt the uptake of Aβ42
by microglia. Thus, extracellular HMGB1 may serve as a
chaperoneproteinforAβ andinhibitmicroglialAβ clearance
by interrupting Aβ40 degradation and Aβ42 internalization
by microglia. On the other hand, RAGE, TLR2, and TLR4
are receptors for HMGB1 [30, 31]; they are also involved
in microglial Aβ phagocytosis [49, 50]. Therefore, there is
a possibility that the interactions of HMGB1 with these
receptorsonmicrogliamayberelatedtotheinhibitoryevents
on Aβ.
Consistent with a previous study [13], plaques con-
taining Aβ42 predominantly existed in AD brains, andInternational Journal of Alzheimer’s Disease 9
Aβ40 accumulated on parts of Aβ42 plaques. Despite the
restricted distribution of Aβ40, almost all plaques containing
Aβ40 were markedly surrounded by activated microglia. We
previously reported that small oligomers formed by Aβ40
strongly induce rat microglial reactions such as cytokine
production [51]. Thus, Aβ40 may play an important role
in microglial activation and/or recruitment on Aβ plaques.
However, we have found that the level of HMGB1 was
signiﬁcantly increased in AD brains [33], and extracellular
HMGB1 accumulated on Aβ plaques. Therefore, in AD
brains, microglial degradation of Aβ40 and uptake of Aβ42
may be inhibited by extracellular HMGB1 despite the
marked accumulation of reactive microglia on Aβ plaques.
Moreover, in the present study, we demonstrated that Aβ40
is more readily degraded by the microglial cytosolic fraction
than Aβ42. However, in the presence of exogenous HMGB1,
the degradation of Aβ40 by microglia is inhibited, and a
lot of Aβ40 granules are existed in the cytoplasm of rat
microglia as shown in Figure 2(f). Interestingly, numerous
microglia containing Aβ40 granules, but not Aβ42, have also
been detected in AD brains [52]. Thus, this event in AD
brain is well replicated by the treatment with Aβ40 in the
presence of extracellular HMGB1 in primary-cultured rat
microglia. Results suggest that our ﬁndings in the eﬀect of
HMGB1 on rat microglia may reﬂect on the pathological
event induced in AD brain and are expected the critical
implication of extracellular HMGB1 in the progression
of AD pathologies. In addition, we have postulated that
the origin of extracellular HMGB1 is leakage from dead
neurons during the progression of AD [32], like ischemic
neurodegeneration [53]. Extracellular HMGB1 leaked from
dead neurons may then accumulate on Aβ plaques through
its binding aﬃnity for Aβ in AD brains.
It has been reported that the released HMGB1 is involved
in the pathologies of various inﬂammatory-related disease
[54]. In ischemic stroke [55] and intracerebral hemor-
rhage especially [56], extracellular HMGB1 is suggested
to exacerbate brain insult through the disruption of the
blood-brain barrier (BBB), overfacilitation of microglia, and
intense production of proinﬂammatory molecules. These
studies also demonstrated that a neutralizing anti-HMGB1
monoclonal antibody and glycyrrhizin which bind to and
inhibit cytokine-like activity of HMGB1 attenuate the brain
insult induced by transient ischemia and intracerebral hem-
orrhage in rat, respectively. Therefore, there is a possibility
that the neutralizing anti-HMGB1 monoclonal antibody
and glycyrrhizin may bind to the extracellular HMGB1
accumulated on the Aβ plaques in the AD brain, cancel the
inhibitory eﬀects of HMGB1 on microglial Aβ phagocytosis,
and then may provide novel therapeutic options for the AD
treatment.
In conclusion, in the present study, we found that
HMGB1 extracellularly accumulates on Aβ plaques con-
taining Aβ40 in AD brains. We further demonstrated
that HMGB1 has a binding aﬃnity for Aβ40, and exoge-
nous HMGB1 is internalized into rat microglial cytoplasm
with Aβ40 and inhibits Aβ40 degradation. Subsequently,
exogenous HMGB1 delays Aβ40 clearance in the culture
medium. Thus, these results suggest that extracellular
HMGB1 attenuates microglial Aβ clearance and is possibly
involved in the progression of AD pathology.
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